{
    "organizations": [],
    "uuid": "32b8900d87a19e7556750cc5b900f0290f51d43e",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ra-capital-management-opposes-bioc/brief-ra-capital-management-opposes-biocryst-pharmaceuticals-proposed-merger-with-idera-pharmaceuticals-idUSFWN1RF07B",
    "ord_in_thread": 0,
    "title": "BRIEF-RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger With Idera Pharmaceuticals",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 2 (Reuters) - Idera Pharmaceuticals Inc:\n* RA CAPITAL MANAGEMENT OPPOSES BIOCRYST PHARMACEUTICALS’ PROPOSED MERGER WITH IDERA PHARMACEUTICALS\n* ‍RA CAPITAL MANAGEMENT SAYS HAS BENEFICIAL OWNERSHIP OF ABOUT 7.1 PERCENT OF BIOCRYST PHARMACEUTICALS’ COMMON STOCK​\n* RA CAPITAL SAYS HAS “SERIOUS CONCERNS” ABOUT BIOCRYST PHARMACEUTICALS’ PROPOSED DEAL WITH IDERA AND ITS “DILUTIVE IMPACT” ON BIOCRYST SHAREHOLDERS ‍​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-02T20:29:00.000+03:00",
    "crawled": "2018-04-03T16:16:38.017+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "idera",
        "pharmaceutical",
        "inc",
        "ra",
        "capital",
        "management",
        "opposes",
        "biocryst",
        "pharmaceutical",
        "proposed",
        "merger",
        "idera",
        "pharmaceutical",
        "capital",
        "management",
        "say",
        "beneficial",
        "ownership",
        "percent",
        "biocryst",
        "pharmaceutical",
        "common",
        "ra",
        "capital",
        "say",
        "serious",
        "concern",
        "biocryst",
        "pharmaceutical",
        "proposed",
        "deal",
        "idera",
        "dilutive",
        "impact",
        "biocryst",
        "shareholder",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}